Ganitumab for Newly Diagnosed Metastatic Ewing Sarcoma

What we are studying

This study will test whether Ganitumab plus standard cancer therapy is more effective than standard therapy alone.

Who is Eligible

  • Genders:
    • Men
    • Women
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • All Ethnicities
  • All Ages up to 50

Eligibility Criteria

  • Metastatic Ewing's Sarcoma
  • No prior therapy
  • Not pregnant or brestfeeding
  • Other requirements (ask your doctor)

What is involved

  • Your doctor will discuss the procedures involved with you.

Compensation

None

Contact Information

Study Coordinator
Graham Keyes
Email
grkeyes@wakehealth.edu
Phone
3367169027

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.